Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Screening for prostate cancer".)
International
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer (2020)
●SIOG: Updated recommendations on prostate cancer management in older patients (2019)
●SIOG: Position paper on radiopharmaceuticals in the elderly cancer patient – Practical considerations, with a focus on prostate cancer therapy (2017)
●Society for Immunotherapy of Cancer (SITC): Consensus statement on immunotherapy for the treatment of prostate carcinoma (2016)
Canada
●Canadian Urological Association (CUA): Best practice report on bone health in prostate cancer (2021)
●CUA-Canadian Urologic Oncology Group (CUOG): Guideline on metastatic castration-naïve and castration-sensitive prostate cancer (2020)
●CUA-CUOG: Guideline for management of castration-resistant prostate cancer (CRPC) (2019)
●Cancer Care Ontario (CCO): Biodegradable rectal spacers for prostate cancer radiotherapy (2019)
●American Society of Clinical Oncology (ASCO)/CCO: Joint guideline on brachytherapy for patients with prostate cancer, update (2017)
●CCO: Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management (2017)
●CCO: Performance of needle biopsy of the prostate for men with suspected or established prostate cancer (2017)
●Choosing Wisely Canada: Don't do routine bone scans in men with low-risk prostate cancer (2017)
●Choosing Wisely Canada: Don't initiate management in patients with low-risk prostate cancer (T1/T2, PSA <10 ng/ml, and Gleason score <7) without first discussing active surveillance (2017)
●Choosing Wisely Canada: Don't order a routine bone scan and CT scan of the pelvis in men with low-risk prostate cancer (2017)
●CCO: Bone health and bone-targeted therapies for prostate cancer (2016)
●CCO: Magnetic resonance imaging for pre-treatment local staging of prostate cancer (2016)
●CCO: Referral of suspected prostate cancer by family physicians and other primary care providers (2016)
●CCO: Follow-up care and psychosocial needs of survivors of prostate cancer (2015)
●CCO: Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer (2015)
●ASCO and CCO: Systemic therapy in men with metastatic castration-resistant prostate cancer (2014)
●CCO: Active surveillance for the management of localized prostate cancer (2014)
●CCO: Risk reduction of prostate cancer with drugs or nutritional supplements (2012)
United States
●National Cancer Institute (NCI): Prostate cancer – Health professional version
●American College of Clinical Oncology (ASCO): Guideline for initial management of noncastrate advanced, recurrent, or metastatic prostate cancer, update (2021)
●ASCO: Bone health and bone-targeted therapies for prostate cancer – Endorsement of a Cancer Care Ontario (CCO) guideline (2020)
●ASCO: Optimum imaging strategies for advanced prostate cancer (2020)
●American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO): Guideline on advanced prostate cancer (2020)
●Philadelphia Prostate Cancer Consensus Conference: Implementation of germline testing for prostate cancer, 2019 (published 2020)
●ASTRO/AUA: Adjuvant and salvage radiotherapy after prostatectomy – Guideline (2013, amended 2019)
●ASCO: Molecular biomarkers in localized prostate cancer (2019)
●AUA/Society of Abdominal Radiology (SAR): Standard operating procedure for multiparametric magnetic resonance imaging in the diagnosis, staging, and management of prostate cancer (revised 2019)
●AUA/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU): Incontinence after prostate treatment – Guideline (2019)
●Choosing Wisely: A routine bone scan is unnecessary in men with very low-risk or low-risk prostate cancer (2013, updated 2019)
●Choosing Wisely: Don't obtain computed tomography scan of the pelvis for asymptomatic men with low-risk clinically localized prostate cancer (2015, updated 2019)
●ASTRO, ASCO, and AUA: Hypofractionated radiation therapy for localized prostate cancer – Evidence-based guideline (2018)
●ASCO: Clinically localized prostate cancer – Clinical practice guideline endorsement of an AUA/ASTRO/SUO guideline (2018)
●AUA: Castration-resistant prostate cancer – Guideline (2013, amended 2018)
●American College of Radiology (ACR): ACR Appropriateness Criteria on post-treatment follow-up on prostate cancer (2017)
●ASCO: Second-line hormonal therapy for men with chemotherapy naïve, castration-resistant prostate cancer – Provisional clinical opinion (2017)
●ASCO/Cancer Care Ontario (CCO): Joint guideline on brachytherapy for patients with prostate cancer, update (2017)
●AUA/ASTRO/SUO: Clinically localized prostate cancer – Guideline (2017)
●Choosing Wisely: Don't initiate management of low-risk prostate cancer without discussing active surveillance (2013, updated 2017)
●Choosing Wisely: Don't treat low-risk clinically localized prostate cancer (eg, Gleason score is less than 7, PSA less than 10.0 ng/mL, and tumor stage T2 or less) without discussing active surveillance as part of the shared decision-making process (2017)
●ACR: ACR Appropriateness Criteria on prostate cancer – Pretreatment detection, surveillance, and staging (2016)
●AUA/SAR: Prostate MRI and MRI-targeted biopsy in patients with prior negative biopsy (2016)
●American Cancer Society (ACS): Prostate cancer survivorship care guidelines (2014)
●ASCO and CCO: Systemic therapy in men with metastatic castration-resistant prostate cancer (2014)
●AUA: Best practice statement – PSA testing for the pretreatment staging and posttreatment management of prostate cancer (2009, amended 2013)
●Choosing Wisely: Don't routinely recommend proton beam therapy for prostate cancer outside of a prospective clinical trial or registry (2013)
●Choosing Wisely: Don't treat an elevated PSA with antibiotics for patients not experiencing other symptoms (2013)
●American Brachytherapy Society (ABS): Consensus guidelines for high-dose-rate prostate brachytherapy (2012)
●ABS: Consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy (2012)
●Choosing Wisely: Don't perform PET, CT, and radionuclide bone scans in the staging of early prostate cancer at low risk for metastasis (2012)
Europe
●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer (2020)
●European Society for Medical Oncology (ESMO): Prostate cancer – Clinical practice guidelines for diagnosis, treatment, and follow-up (2020)
●European Organisation for Research and Treatment of Cancer (EORTC): Guidelines for target volume definition in post-operative radiotherapy for prostate cancer (2007)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Guideline on prostate cancer – Diagnosis and management (2019, updated 2021)
●NICE: Quality standard on prostate cancer (2015, updated 2021)
●Prostate Cancer UK: Consensus statements on PSA testing in asymptomatic men in the UK – Information for health professionals (2016)
●Public Health England (PHE): Guidance for the prostate cancer risk management programme (PCRMP) – Benefits and risks of PSA testing (2016)
Australia-New Zealand
●Choosing Wisely Australia: Don't initiate management of low risk prostate cancer without discussing active surveillance
●Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG): Guidelines on radiotherapy for node-positive prostate cancer – Recommendations (2019)
●Royal Australian College of General Practitioners (RACGP): Guidelines for preventive activities in general practice, 9th edition (2018)
•Prostate cancer
●Prostate Cancer Foundation of Australia (PCFA) and Cancer Council Australia (CCA): Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer (2016)
●Prostate Cancer Working Group and Ministry of Health: Guidance on using active surveillance to manage men with low-risk prostate cancer (2015)
●Prostate Cancer Working Group and Ministry of Health: Prostate cancer management and referral guidance (2015)
●Australian National Health and Medical Research Council (NHMRC): Prostate-specific antigen (PSA) testing in asymptomatic men (2014)
●Prostate Cancer Taskforce: Diagnosis and management of prostate cancer in New Zealand men – Recommendations (2013)
●CCA and Australian Cancer Network (ACN): Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer (2010)
Japan
●[In Japanese] Choosing Wisely Japan: Low-risk prostate cancer – Do not be rushed (2018)
●[In English] Japanese Urological Association (JUA): Evidence-based clinical practice guideline for prostate cancer, 2016 edition (published 2017)
●[In Japanese] JUA: Clinical practice guideline for prostate cancer (2016)
